mycobacterium tuberculosis slide share ..
2
Prepared by :ABDULLAH
Introduction
 TB is one of the oldest recorded
human afflictions
 Still one of the biggest killers
among the infectious diseases
 The bacillus causing tuberculosis,
Mycobacterium tuberculosis, was
identified and described on
March 24, 1882 by Robert Koch
 One-third of the
world's population is
currently infected with
TB
 with 8 to 10 million new
cases each year.
 2 million TB related
deaths/year
Epidmiology
Incidence and prevelance
M. tuberculosis
M. bovis
M. africanum
M. microti
M. canettii
M. caprae
M. pinnipedii
Etiology
Human tuberculosis (TB) is caused by
infection with members of the
Mycobacterium tuberculosis complex, which
includes :
Characteristics of M.tuberclosis
 Slightly curved,rod shaped bacilli
 Aerobic, Non motile
 Thick lipid cell wall,resist
decolorization with acidified
alcohol
“ Acid fast bacteria”
 Multiplies slowly”every 18 - 24
hrs”
 Can remain dormant for
decades
 Person-to-person
through the air by a
person with TB
disease of the lungs
 Less frequently transmitted by:
• Ingestion of Mycobacterium bovis
found in unpasteurized milk products
• Laboratory accident
How is TB Transmitted
?
Source: CDC, 2000
The probability that TB will be transmitted
from one person to another depends on a
number of factors
 The concentration of TB bacteria in the air
 The environment in which exposure to the
bacteria occurs
 The length of time of exposure
 Person‘ s immune system
Risk factors
 Co infection with HIV
 Diabetic person
 Persons undergo chemotherapy
 Person undergo organ
transplantation
 Extreme ages,children and geriatric
 Malnutration
Pathogenesis
mycobacterium tuberculosis slide share ..
Active TB Disease
Germs:
 Awake and multiplying
 Cause damage to the lungs
Person:
 Most often feels sick
 Contagious (before pills started)
 Usually have a positive tuberculin
skin test
 Chest X-ray is often abnormal
(with pulmonary TB)
Granuloma breaks
down and tubercle
escape and multiply
TB
Germs:
 Sleeping but still alive
 Surrounded (walled off)
by body’s immune system
Person:
 Not ill
 Not contagious
 Normal chest x-ray
 Usually the tuberculin
skin test is positive
Latent TB infection(LTBI)
mycobacterium tuberculosis slide share ..
Spread of TB to Other Parts of the Body
1. Lungs (85% all cases)
2. Pleura
3. Central nervous system
• (e.g., brain, meninges)
4. Lymph nodes
5. Genitourinary system
6. Bones and joints
7. Disseminated
 (e.g., miliary)
© ITECH, 2006
Extrapulmonary TB
Pleura
Lymph Node
Brain
Spine
Symptoms
Diagnosis
 Medical history
 Physical examination
 Sputum smear microscopy
Acid fast staining (Ziehl–Neelsen stain)
Fluorochrome stain using fluorescence microscopy
 Culture
 Immunological tests
 TB skin test(Tuberculin skin test )
 TB blood tests
 Chest radiograph (X-ray)
 PCR
Bacteriologic Examination of Clinical
Specimens
 The bacteriologic examination has five parts:
 Specimen collection, processing, and review
 AFB smear classification and results
 Direct detection of M. tuberculosis in clinical specimen
using nucleic acid amplification (NAA)
 Specimen culturing and identification
 Drug-susceptibility testing
Specimen Collection, Processing, and
Review
 At least three consecutive
sputum specimens are needed,
each collected in 8- to 24-hour
intervals, with at least one being
an early morning specimen.
 If possible, specimens should be
obtained in an airborne infection
isolation (AII) room or other
isolated, well-ventilated area
(e.g., outdoors)
Specimen Collection
Methods
 Coughing
 Induced sputum
 Bronchoscopy
 Gastric aspiration
Specimen Collection, Processing, and
Review
Sputum smear microscopy
a. Ziehl-Neelsen stain
 fixed smear covered with
carbol-fuchsin, heated, rinsed,
 decolorized with acid
alcoholb.
b. Fluorochrome stain with
phenol-auramine
 modified acid alcohol step
 potassium permanganate
counter staining; fluorescent
 Mycobacteria visible with 20
or 40X magnification
 SMEAR POSITIVITY MEANS
AT LEAST 10,000
ORGANISMS/mL SPUTUM Fluorochrome stain
Culture (Gold Standard)
a. Solid media
Lowenstein Jensen (egg based)
Middlebrook 7H11 (agar based)
 can detect colony morphology,
mixed infections; can detect 10-
100
 organisms/mL; 3-8 weeks
incubation to detect organisms
b. Liquid broth
Middlebrook 7H12, BACTEC
systems
 1-3 weeks of incubation to
detect organisms
M.Tuberclosis on
Lowenstein Jensen media
Buff colonies
TB skin test(Tuberculin skin test)
 Called the Mantoux
tuberculin skin test
 Result depends on the
size of the raised, hard
area or swelling
 Also depends on the
person’s risk of being
infected with TB bacteria
and the progression to TB
disease if infected.
TB blood tests
(Interferon-Gamma Release Assays,
IGRAs)
 Measures how strong a person’s
immune system reacts to TB bacteria
 Two IGRAs

QuantiFERON®–TB Gold In-Tube test (QFT-GIT

T-SPOT®.TB test (T-Spot)
 IGRAs are the preferred method of TB
infection testing for
 People who have received bacille Calmette–
Guérin (BCG). BCG is a vaccine for TB disease.
 People who have a difficult time returning
for a second appointment to look for a
reaction to the TST.
TB blood tests
(interferon-gamma release assays, IGRAs)
TB treatment is challenging, requiring
accurate and early diagnosis,
drug‑resistance screening and the
administration of effective treatment
regimens for at least 6 months through
( Directly Observed Therapy (DOT) and
follow‑up support.
Treatment for tuberculosis (TB) depends on
which type you have, although a long course
of antibiotics is most often used
Treatment
 The goals of TB treatment are to:
1. Shorten the clinical course of TB
2. Prevent complications
3. Prevent the development of latency
and/or subsequent recurrences
4. Decrease the likelihood of TB
transmission
Treatment
 First-line anti-TB drugs
recommended in a four-drug
combination
for the treatment of drug-
susceptible TB.
 Second-line anti-TB drugs
for drug-resistant TB.
Treatment
First line
Drug (year of
discovery)
Target
Effect
activity
Isoniazid (1952)
Enoyl-(acyl
carrier protein)
reductase
Inhibit mycolic
acid synthesis
bactericidal
Rifampicin (1963)
RNA polymerase
Beta subunit
Inhibit
transcription
bactericidal
Pyrazinamide
(1954)
Exact target
unknowen
Disrupt plasma
memb.
Disrupt energy
memb.
bacteriostatic
Ethambutol
(1961)
Arabinosyl
transferase
Inhibit
arabinogalactan
biosynthesis
bacteriostatic
First-line anti-TB drugs
First line
Regimens Of Antituberculosis Drugs
Active disease
Treatment requires a minimum of 6 months in two phases
Intensive phase
Isoniazid,rifampin,ethambutol and pyrazinamide”given
for 2 months”
Continuation phase
Isoniazid and rifampin”for 4 months
Latent disease
Daily isoniazid therapy for 9 monthes
“Monitor the patient for signs and symptoms of hepatitis and
peripheral neuropathy”
Regimens Of Antituberculosis Drugs
Second line
Drug
target
effect
Para-amino
salicylic
acid )PAS`)
Dihydro _pteroate
synthase
Inhibits folate
biosynthesis
Ethionamide
Enoyl-[acyl-carrier-
protein] reductase
Inhibits mycolic acid
biosynthesis
Ofloxacin
DNA gyrase and DNA
topoisomerase
Inhibits DNA
supercoiling
Kanamycin
30S ribosomal subunit
Inhibits protein
synthesis
Amikacin
30S ribosomal subunit
Inhibits protein
synthesis
Cycloserin
d-alanine racemase and
ligase
Inhibits
peptidoglycan
synthesis
Second line
Resistance
Two types
 Primary”intrinsic” resistance
Infection with strains naturally resistant to one or
two drugs

Hydrophobic cell wall

Drug modifying enzymes
 Drug efflux system
 Acquired resistance
Infection with strains that become drug resistant
d.t inappropriate or inadequate treatment
Drug resistance in TB
 MDR (Multi-Drug Resistant)
Simultanous resistance to 2 or more
drugs from 1st
line
 XDR (Extensive Drug Resistance)
Strains not only resistant to 1st
line but
also resist fluoroquiolones and one of
injectible drugs
{ kanamicin,amikacin,capreomycin}
How can tuberculosis be prevented
?
 The BCG vaccine.
It usually protects children and infants from the
disease, but its effects wear off when the patient
reaches adulthood.
 Eating a healthful diet that boosts the immune
system
 Having regular TB tests if you work or live in
a high risk environment
 Completing a TB medication regimen.
 If you are infected, stay home, cover your mouth, and
ensure proper ventilation.
mycobacterium tuberculosis slide share ..

More Related Content

PPT
Tuberclosis
PPTX
pulmonary tuberculosis
PPT
mycobacteria -TB.ppt- laboratory medicine
PPT
Tuberculosis
PPT
Laboratory diagnosis of Tuberculosis gs
PPTX
Introduction ot Tuberculosis disease (TB)
PPTX
Jai cmb
PPT
Mycobacterium tuberculosis and Mycobacterium leprae
Tuberclosis
pulmonary tuberculosis
mycobacteria -TB.ppt- laboratory medicine
Tuberculosis
Laboratory diagnosis of Tuberculosis gs
Introduction ot Tuberculosis disease (TB)
Jai cmb
Mycobacterium tuberculosis and Mycobacterium leprae

Similar to mycobacterium tuberculosis slide share .. (20)

PPT
Pulmonary Tuberculosis and its presentationss.ppt
PPTX
DPT - Microbiology II (Acid fast Bacilli) - Mycobacteria
PPTX
Tuberculosis Tutorial By Akugizibwe Solomon (MBChB IV).pptx
PPTX
Tuberculosis presentation by Sohel Memon
PPTX
Tuberculosis
PPTX
2nd term lectures,_cd,_listeria,diphoids[1]
PPT
Pulmonary Tuberculosis
PPTX
Impact of tuberculosis pathogenesis and management
PDF
Tuberculosis
PDF
Anti TB drugs
PPT
Mycobacteria.pptMycobacterium tuberculosis It is currently estimated that abo...
PPT
Diagnosis for tuberculosis(1).ppt2003
PPTX
Definition of tuberculosis as scientific and practical problem
PPTX
Tuberculosis
PPTX
TUBERCULOSIS. .pptx
PPT
Tuberculosis
PDF
tuberculosis-150808111627-lva1-app6891.pdf
PPTX
Tuberculosis
PPTX
Microbiology Gram Positive Bacillig.pptx
PPT
Tuberculosis diagnosis by dr najeeb
Pulmonary Tuberculosis and its presentationss.ppt
DPT - Microbiology II (Acid fast Bacilli) - Mycobacteria
Tuberculosis Tutorial By Akugizibwe Solomon (MBChB IV).pptx
Tuberculosis presentation by Sohel Memon
Tuberculosis
2nd term lectures,_cd,_listeria,diphoids[1]
Pulmonary Tuberculosis
Impact of tuberculosis pathogenesis and management
Tuberculosis
Anti TB drugs
Mycobacteria.pptMycobacterium tuberculosis It is currently estimated that abo...
Diagnosis for tuberculosis(1).ppt2003
Definition of tuberculosis as scientific and practical problem
Tuberculosis
TUBERCULOSIS. .pptx
Tuberculosis
tuberculosis-150808111627-lva1-app6891.pdf
Tuberculosis
Microbiology Gram Positive Bacillig.pptx
Tuberculosis diagnosis by dr najeeb
Ad

Recently uploaded (20)

PPTX
Nancy Caroline Emergency Paramedic Chapter 8
PPTX
Benign prostatic hyperplasia, uro anaesthesia
PPTX
Acute renal failure.pptx for BNs 2nd year
PDF
crisisintervention-210721062718.presentatiodnf
PPTX
Nancy Caroline Emergency Paramedic Chapter 14
PDF
cerebral aneurysm.. neurosurgery , anaesthesia
PPTX
Obstetric management in women with epilepsy.pptx
PPTX
Full Slide Deck - SY CF Talk Adelaide 10June.pptx
PPTX
unit1-introduction of nursing education..
PPTX
guidance--unit 1 semester-5 bsc nursing.
PPTX
Nancy Caroline Emergency Paramedic Chapter 1
PPTX
Newer Technologies in medical field.pptx
PPTX
HIGHLIGHTS of NDCT 2019 WITH IMPACT ON CLINICAL RESEARCH.pptx
PDF
Culturally Sensitive Health Solutions: Engineering Localized Practices (www....
PDF
01. Histology New Classification of histo is clear calssification
PPT
Pyramid Points Acid Base Power Point (10).ppt
PPTX
ACUTE CALCULAR CHOLECYSTITIS: A CASE STUDY
DOCX
ch 9 botes for OB aka Pregnant women eww
PPTX
Nancy Caroline Emergency Paramedic Chapter 17
PPTX
Nancy Caroline Emergency Paramedic Chapter 16
Nancy Caroline Emergency Paramedic Chapter 8
Benign prostatic hyperplasia, uro anaesthesia
Acute renal failure.pptx for BNs 2nd year
crisisintervention-210721062718.presentatiodnf
Nancy Caroline Emergency Paramedic Chapter 14
cerebral aneurysm.. neurosurgery , anaesthesia
Obstetric management in women with epilepsy.pptx
Full Slide Deck - SY CF Talk Adelaide 10June.pptx
unit1-introduction of nursing education..
guidance--unit 1 semester-5 bsc nursing.
Nancy Caroline Emergency Paramedic Chapter 1
Newer Technologies in medical field.pptx
HIGHLIGHTS of NDCT 2019 WITH IMPACT ON CLINICAL RESEARCH.pptx
Culturally Sensitive Health Solutions: Engineering Localized Practices (www....
01. Histology New Classification of histo is clear calssification
Pyramid Points Acid Base Power Point (10).ppt
ACUTE CALCULAR CHOLECYSTITIS: A CASE STUDY
ch 9 botes for OB aka Pregnant women eww
Nancy Caroline Emergency Paramedic Chapter 17
Nancy Caroline Emergency Paramedic Chapter 16
Ad

mycobacterium tuberculosis slide share ..

  • 3. Introduction  TB is one of the oldest recorded human afflictions  Still one of the biggest killers among the infectious diseases  The bacillus causing tuberculosis, Mycobacterium tuberculosis, was identified and described on March 24, 1882 by Robert Koch
  • 4.  One-third of the world's population is currently infected with TB  with 8 to 10 million new cases each year.  2 million TB related deaths/year Epidmiology Incidence and prevelance
  • 5. M. tuberculosis M. bovis M. africanum M. microti M. canettii M. caprae M. pinnipedii Etiology Human tuberculosis (TB) is caused by infection with members of the Mycobacterium tuberculosis complex, which includes :
  • 6. Characteristics of M.tuberclosis  Slightly curved,rod shaped bacilli  Aerobic, Non motile  Thick lipid cell wall,resist decolorization with acidified alcohol “ Acid fast bacteria”  Multiplies slowly”every 18 - 24 hrs”  Can remain dormant for decades
  • 7.  Person-to-person through the air by a person with TB disease of the lungs  Less frequently transmitted by: • Ingestion of Mycobacterium bovis found in unpasteurized milk products • Laboratory accident How is TB Transmitted ? Source: CDC, 2000
  • 8. The probability that TB will be transmitted from one person to another depends on a number of factors  The concentration of TB bacteria in the air  The environment in which exposure to the bacteria occurs  The length of time of exposure  Person‘ s immune system
  • 9. Risk factors  Co infection with HIV  Diabetic person  Persons undergo chemotherapy  Person undergo organ transplantation  Extreme ages,children and geriatric  Malnutration
  • 12. Active TB Disease Germs:  Awake and multiplying  Cause damage to the lungs Person:  Most often feels sick  Contagious (before pills started)  Usually have a positive tuberculin skin test  Chest X-ray is often abnormal (with pulmonary TB) Granuloma breaks down and tubercle escape and multiply TB
  • 13. Germs:  Sleeping but still alive  Surrounded (walled off) by body’s immune system Person:  Not ill  Not contagious  Normal chest x-ray  Usually the tuberculin skin test is positive Latent TB infection(LTBI)
  • 15. Spread of TB to Other Parts of the Body 1. Lungs (85% all cases) 2. Pleura 3. Central nervous system • (e.g., brain, meninges) 4. Lymph nodes 5. Genitourinary system 6. Bones and joints 7. Disseminated  (e.g., miliary) © ITECH, 2006
  • 18. Diagnosis  Medical history  Physical examination  Sputum smear microscopy Acid fast staining (Ziehl–Neelsen stain) Fluorochrome stain using fluorescence microscopy  Culture  Immunological tests  TB skin test(Tuberculin skin test )  TB blood tests  Chest radiograph (X-ray)  PCR
  • 19. Bacteriologic Examination of Clinical Specimens  The bacteriologic examination has five parts:  Specimen collection, processing, and review  AFB smear classification and results  Direct detection of M. tuberculosis in clinical specimen using nucleic acid amplification (NAA)  Specimen culturing and identification  Drug-susceptibility testing
  • 20. Specimen Collection, Processing, and Review  At least three consecutive sputum specimens are needed, each collected in 8- to 24-hour intervals, with at least one being an early morning specimen.  If possible, specimens should be obtained in an airborne infection isolation (AII) room or other isolated, well-ventilated area (e.g., outdoors)
  • 21. Specimen Collection Methods  Coughing  Induced sputum  Bronchoscopy  Gastric aspiration Specimen Collection, Processing, and Review
  • 22. Sputum smear microscopy a. Ziehl-Neelsen stain  fixed smear covered with carbol-fuchsin, heated, rinsed,  decolorized with acid alcoholb. b. Fluorochrome stain with phenol-auramine  modified acid alcohol step  potassium permanganate counter staining; fluorescent  Mycobacteria visible with 20 or 40X magnification  SMEAR POSITIVITY MEANS AT LEAST 10,000 ORGANISMS/mL SPUTUM Fluorochrome stain
  • 23. Culture (Gold Standard) a. Solid media Lowenstein Jensen (egg based) Middlebrook 7H11 (agar based)  can detect colony morphology, mixed infections; can detect 10- 100  organisms/mL; 3-8 weeks incubation to detect organisms b. Liquid broth Middlebrook 7H12, BACTEC systems  1-3 weeks of incubation to detect organisms M.Tuberclosis on Lowenstein Jensen media Buff colonies
  • 24. TB skin test(Tuberculin skin test)  Called the Mantoux tuberculin skin test  Result depends on the size of the raised, hard area or swelling  Also depends on the person’s risk of being infected with TB bacteria and the progression to TB disease if infected.
  • 25. TB blood tests (Interferon-Gamma Release Assays, IGRAs)  Measures how strong a person’s immune system reacts to TB bacteria  Two IGRAs  QuantiFERON®–TB Gold In-Tube test (QFT-GIT  T-SPOT®.TB test (T-Spot)
  • 26.  IGRAs are the preferred method of TB infection testing for  People who have received bacille Calmette– Guérin (BCG). BCG is a vaccine for TB disease.  People who have a difficult time returning for a second appointment to look for a reaction to the TST. TB blood tests (interferon-gamma release assays, IGRAs)
  • 27. TB treatment is challenging, requiring accurate and early diagnosis, drug‑resistance screening and the administration of effective treatment regimens for at least 6 months through ( Directly Observed Therapy (DOT) and follow‑up support. Treatment for tuberculosis (TB) depends on which type you have, although a long course of antibiotics is most often used Treatment
  • 28.  The goals of TB treatment are to: 1. Shorten the clinical course of TB 2. Prevent complications 3. Prevent the development of latency and/or subsequent recurrences 4. Decrease the likelihood of TB transmission Treatment
  • 29.  First-line anti-TB drugs recommended in a four-drug combination for the treatment of drug- susceptible TB.  Second-line anti-TB drugs for drug-resistant TB. Treatment
  • 31. Drug (year of discovery) Target Effect activity Isoniazid (1952) Enoyl-(acyl carrier protein) reductase Inhibit mycolic acid synthesis bactericidal Rifampicin (1963) RNA polymerase Beta subunit Inhibit transcription bactericidal Pyrazinamide (1954) Exact target unknowen Disrupt plasma memb. Disrupt energy memb. bacteriostatic Ethambutol (1961) Arabinosyl transferase Inhibit arabinogalactan biosynthesis bacteriostatic First-line anti-TB drugs
  • 33. Regimens Of Antituberculosis Drugs Active disease Treatment requires a minimum of 6 months in two phases Intensive phase Isoniazid,rifampin,ethambutol and pyrazinamide”given for 2 months” Continuation phase Isoniazid and rifampin”for 4 months Latent disease Daily isoniazid therapy for 9 monthes “Monitor the patient for signs and symptoms of hepatitis and peripheral neuropathy”
  • 35. Second line Drug target effect Para-amino salicylic acid )PAS`) Dihydro _pteroate synthase Inhibits folate biosynthesis Ethionamide Enoyl-[acyl-carrier- protein] reductase Inhibits mycolic acid biosynthesis Ofloxacin DNA gyrase and DNA topoisomerase Inhibits DNA supercoiling Kanamycin 30S ribosomal subunit Inhibits protein synthesis Amikacin 30S ribosomal subunit Inhibits protein synthesis Cycloserin d-alanine racemase and ligase Inhibits peptidoglycan synthesis
  • 37. Resistance Two types  Primary”intrinsic” resistance Infection with strains naturally resistant to one or two drugs  Hydrophobic cell wall  Drug modifying enzymes  Drug efflux system  Acquired resistance Infection with strains that become drug resistant d.t inappropriate or inadequate treatment
  • 38. Drug resistance in TB  MDR (Multi-Drug Resistant) Simultanous resistance to 2 or more drugs from 1st line  XDR (Extensive Drug Resistance) Strains not only resistant to 1st line but also resist fluoroquiolones and one of injectible drugs { kanamicin,amikacin,capreomycin}
  • 39. How can tuberculosis be prevented ?  The BCG vaccine. It usually protects children and infants from the disease, but its effects wear off when the patient reaches adulthood.  Eating a healthful diet that boosts the immune system  Having regular TB tests if you work or live in a high risk environment  Completing a TB medication regimen.  If you are infected, stay home, cover your mouth, and ensure proper ventilation.

Editor's Notes

  • #5: There are several other species and subspecies that are included in the Mycobacterium tuberculosis complex because of their close genetic relationship to tuberculosis: [Review the slide content] With the exception of M. pinnipedii, all of the species in the Mycobacterium tuberculosis complex have been shown to cause disease in humans; however, M. tuberculosis is by far the most prevalent Mycobacterium tuberculosis is the organism responsible for most of the tuberculosis infection and disease seen in the Caribbean Image Credit: CDC Public Health Image Library/Dr. George P. Kubica
  • #7: Pose question to participants “How is TB transmitted?” Solicit their responses then proceed to review slide content Transmission is the spread of organisms, such as M. tuberculosis, from one person to another The primary mode of transmission for tuberculosis is through inhalation of infectious particles Less frequently, TB can be transmitted by:…[Review slide content] *Slide Animation Image Credit: Cartoon from clip art.; Graphic from CDC Core Curriculum. 2000.
  • #12: Review the slide content Tuberculosis disease can develop very soon after infection or many years after infection In individuals without HIV co-infection, about 5% of people who have been recently infected with M. tuberculosis will develop TB disease in the first year or two after infection. Another 5% will develop disease later in their lives. The remaining 90% will stay infected, but free of disease for the rest of their lives It’s important to remember that not all patients with active TB disease will have a positive Mantoux TST (approx. 75% will have +TST and this percentage is lower in HIV infected patients). Never stop evaluating a patient for active TB simply because the Mantoux TST is 00mm! The chest X-ray will often show abnormalities suggestive of active TB but may be within normal limits for some patients with active disease, particularly if they also have HIV. This will be covered in more detail in Module 4 on Case Finding and Diagnosis Image Source: Centers for Disease Control and Prevention (CDC)
  • #13: If the immune system is compromised, then the bacilli multiply and spread to other sites in the body. People who have TB infection but not TB disease are NOT infectious - in other words, they cannot spread the infection to other people Persons with LTBI have a low bacillary load (e.g., ≤~103) It is very important to remember that TB infection is not considered a case of TB Image Source: Centers for Disease Control and Prevention (CDC)
  • #15: This next section describes the pathogenesis of TB (the way TB infection and disease develop in the body) At first, the tubercle bacilli multiply in the alveoli and a small number enter the bloodstream and spread throughout the body (dissemination) Bacilli may reach any part of the body, including areas where TB disease is more likely to develop. These areas include the upper portions of the lungs, as well as the kidneys, the brain, and bone Disseminated TB refers to TB that simultaneously involves multiple organs. While “miliary” is given as an example of disseminated TB, it really refers to a radiographic manifestation of disseminated TB. It’s important to note that not all patients with disseminated TB have a miliary pattern on CXR Image source: I-TECH
  • #16: This slide shows different sites where TB has caused disease outside of the lungs Image Sources: Scrofula: http://farm1.static.flickr.com/110/283397827_f071de4335_m.jpg Radiographic images: Francis J. Curry National Tuberculosis Center